Literature DB >> 18753474

Symptomatic intracerebral hemorrhage and recanalization after IV rt-PA: a multicenter study.

M Saqqur1, G Tsivgoulis, C A Molina, A M Demchuk, M Siddiqui, J Alvarez-Sabín, K Uchino, S Calleja, A V Alexandrov.   

Abstract

BACKGROUND: Symptomatic intracerebral hemorrhage (sICH) is the most unfavorable complication after IV thrombolytic treatment. We aimed to determine the relationship between early recanalization and the risk of sICH.
METHODS: Patients with acute stroke received IV tissue plasminogen activator (rt-PA) within 3 hours of symptom onset with transcranial Doppler (TCD) monitoring at four academic centers. sICH was defined as parenchymal hemorrhage on CT in relation to neurologic worsening (NIH Stroke Scale [NIHSS] > or = 4) within 72 hours after treatment. Poor outcome was defined as modified Rankin Scale 3-6 at 3 months. Early recanalization was graded with Thrombolysis in Brain Ischemia (TIBI) system. Multiple logistic regression analyses were used to identify predictors of sICH.
RESULTS: A total of 349 patients received rt-PA at median 134 +/- 32 minutes (mean age 69 +/- 13 years, 186 men [53%]). Median pretreatment NIHSS score was 16 points (interquartile range: 12-20). Median time to TCD was 130 +/- 40 minutes. At the end of rt-PA infusion, 135 patients (38%) had no recanalization, 101 (29%) partial, and 113 (32%) complete recanalization. sICH occurred in 26 patients (7.4%). Of the 135 patients without early recanalization, 18 (13%) had sICH, as compared to 4 (4%) of the 109 subjects with partial recanalization and 4 (3.5%) of 113 with complete recanalization, p = 0.005. After adjustment for age, sex, baseline NIHSS score, glucose, blood pressure, and time to treatment, patients with persistent occlusion had sixfold higher risk of sICH (OR = 6, 95% CI 1.5-21.3, p = 0.01).
CONCLUSION: The risk of tPA-related symptomatic intracerebral hemorrhage (sICH) is low after early and complete restoration of blood flow. Arterial occlusion persistent beyond tissue plasminogen activator infusion emerges as an independent predictor of higher risk of sICH in patients treated with systemic thrombolysis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18753474     DOI: 10.1212/01.wnl.0000313936.15842.0d

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  21 in total

1.  Systemic thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke: first Croatian experiences.

Authors:  Vesna Matijević; Domagoj Alvir; Branko Malojčić; Lea Unušić; Svjetlana Supe; Marina Boban; Andrea Bujan-Kovač; Mario Habek; Zdravka Poljaković
Journal:  Neurol Sci       Date:  2010-03-06       Impact factor: 3.307

2.  Comment on: A cost-utility analysis of mechanical thrombectomy as an adjunct of intravenous tissue-type plasminogen activator for acute large-vessel ischemic stroke: Kim AS, Nguyen-Huynh M, Johnston SC. Stroke 2011;42:2013-2018.

Authors:  J Kollmer; S Rohde
Journal:  Clin Neuroradiol       Date:  2011-09       Impact factor: 3.649

Review 3.  Antiplatelet pretreatment and outcomes in intravenous thrombolysis for stroke: a systematic review and meta-analysis.

Authors:  Georgios Tsivgoulis; Aristeidis H Katsanos; Ramin Zand; Vijay K Sharma; Martin Köhrmann; Sotirios Giannopoulos; Efthymios Dardiotis; Anne W Alexandrov; Panayiotis D Mitsias; Peter D Schellinger; Andrei V Alexandrov
Journal:  J Neurol       Date:  2017-05-26       Impact factor: 4.849

Review 4.  Clinical trials in acute ischemic stroke.

Authors:  Kiyoshi Kikuchi; Eiichiro Tanaka; Yoshinaka Murai; Salunya Tancharoen
Journal:  CNS Drugs       Date:  2014-10       Impact factor: 5.749

5.  Predictors of subarachnoid hemorrhage in acute ischemic stroke with endovascular therapy.

Authors:  Zhong-Song Shi; David S Liebeskind; Yince Loh; Jeffrey L Saver; Sidney Starkman; Paul M Vespa; Nestor R Gonzalez; Satoshi Tateshima; Reza Jahan; Lei Feng; Chad Miller; Latisha K Ali; Bruce Ovbiagele; Doojin Kim; Gary R Duckwiler; Fernando Viñuela
Journal:  Stroke       Date:  2010-11-04       Impact factor: 7.914

6.  Use of intravenous recombinant tissue plasminogen activator in patients with borderline elevation of international normalized ratio.

Authors:  Harsh R Aggarwal; Ameer E Hassan; Gustavo J Rodriguez; M Fareed K Suri; Robert A Taylor; Adnan I Qureshi
Journal:  J Vasc Interv Neurol       Date:  2013-12

7.  Direct thrombus aspiration using the Penumbra system for the treatment of pediatric intracranial dissection.

Authors:  Motoaki Fujimoto; Satoshi Tateshima; Latisha Ali; Radoslav Raychev; Fernando Vinuela
Journal:  BMJ Case Rep       Date:  2012-11-15

8.  Advanced imaging improves prediction of hemorrhage after stroke thrombolysis.

Authors:  Bruce C V Campbell; Søren Christensen; Mark W Parsons; Leonid Churilov; Patricia M Desmond; P Alan Barber; Kenneth S Butcher; Christopher R Levi; Deidre A De Silva; Maarten G Lansberg; Michael Mlynash; Jean-Marc Olivot; Matus Straka; Roland Bammer; Gregory W Albers; Geoffrey A Donnan; Stephen M Davis
Journal:  Ann Neurol       Date:  2013-02-26       Impact factor: 10.422

9.  Sonothrombolysis in ischemic stroke.

Authors:  Kristian Barlinn; Andrei V Alexandrov
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

10.  Atorvastatin extends the therapeutic window for tPA to 6 h after the onset of embolic stroke in rats.

Authors:  Li Zhang; Michael Chopp; Longfei Jia; Yisheng Cui; Mei Lu; Zheng Gang Zhang
Journal:  J Cereb Blood Flow Metab       Date:  2009-07-29       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.